97 related articles for article (PubMed ID: 20805747)
1. Advances in understanding and management of polycythemia vera.
Vannucchi AM; Guglielmelli P
Curr Opin Oncol; 2010 Nov; 22(6):636-41. PubMed ID: 20805747
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
5. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
Ohyashiki JH
Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
[TBL] [Abstract][Full Text] [Related]
8. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
9. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
10. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
12. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
13. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
14. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
15. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
17. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
18. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
19. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera: diagnosis, clinical course, and current management.
Büyükaşik Y; Alİ R; Ar C; Turgut M; Yavuz S; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):698-710. PubMed ID: 30114348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
